Industry expresses concern over US FDA guideline on device changes needing new 510(k)s
This article was originally published in SRA
Executive Summary
US medtech industry association AdvaMed warns that the number of pre-market notification applications that are submitted for device modifications could rise by 300-500% if a recent draft guideline by the Food and Drug Administration is implemented1. The association is concerned that the proposals in the draft document would result in the submission of more applications than the FDA can handle, resulting in unnecessary delays in the processing of submissions for new technologies and in patient access to modified devices.
You may also be interested in...
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Regulators Explain How To Ensure Transitioned Trials Align With CTR
Members of the EU’s Clinical Trials Coordination Group have developed harmonized requirements for updating trials that are transitioned to the Clinical Trials Information System based on a minimum set of documents.